NCT01268930

Brief Summary

In this study, impacts of hemostatic matrix and bipolar electrocoagulation on ovarian reserve in women undergoing ovarian endometrioma excision are compared.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2010

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2010

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 3, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 4, 2011

Completed
28 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2011

Completed
Last Updated

June 22, 2011

Status Verified

December 1, 2010

Enrollment Period

5 months

First QC Date

January 3, 2011

Last Update Submit

June 21, 2011

Conditions

Keywords

ovarian reserveendometrioma excisionhemostatic matrixbipolar electrocoagulationthermal injury

Outcome Measures

Primary Outcomes (1)

  • preoperative and at 1 and 3 months postoperatively ovarian reserve differences will be measured by serum anti mullerian hormone between two groups (hemostatic matrix and bipolar coagulation groups)

    Group 1: after excision of ovarian endometrioma with its wall hemostatic matrix is used to provide hemostasis in the bed of endometrioma. Group 2: after excision of ovarian endometrioma with its wall bipolar elektrocoagulation is used to provide hemostasis in the bed of endometrioma. At the end of study antimullerian hormone values as an indicator of ovarian reserve will be compared.

    within preoperative 1 week, postoperative at 1 and 3 months

Study Arms (2)

Bipolar coagulation

ACTIVE COMPARATOR

In this arm, after the complete excision of ovarian endometrioma, ovarian hemostasis is provided by bipolar electrocoagulation.

Procedure: Bipolar electrocautery for ovarian hemostasis

Hemostatic matrix

ACTIVE COMPARATOR

In this arm, after complete excision of ovarian endometrioma, ovarian hemostasis is provided by hemostatic matrix.

Procedure: hemostatic matrix (FloSeal)

Interventions

after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.

Bipolar coagulation

after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.

Hemostatic matrix

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients in reproductive ages
  • Presence of ovarian endometrioma at least 4 centimeter in size

You may not qualify if:

  • Previous ovarian surgery
  • Pregnancy
  • Lactation
  • Diabetes Mellitus, thyroid or adrenal disorders, hyperprolactinemia
  • History or suspicion of malignancy
  • Use of oral contraceptive drug, GnRH agonist or antagonist, danazol and other drug relation with ovarian function in last 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara University Medical Faculty Hospital

Ankara, 06100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Endometriosis

Interventions

FloSeal Matrix

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 3, 2011

First Posted

January 4, 2011

Study Start

September 1, 2010

Primary Completion

February 1, 2011

Study Completion

March 1, 2011

Last Updated

June 22, 2011

Record last verified: 2010-12

Locations